ReviewFrontiers in cell and developmental biology2020
Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer.
Review in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy.Oncology research · 2026Review
- Targeting cancer via macrophage-derived exosomal miRNAs: implications for tumor progression and resistance.Frontiers in immunology · 2025Review
- Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.Journal of clinical medicine · 2024Review
- Review
- EBV-associated epithelial cancers cells promote vasculogenic mimicry formation via a secretory cross-talk with the immune microenvironment.Theranostics · 2024Article
- Exosomes: a promising avenue for cancer diagnosis beyond treatment.Frontiers in cell and developmental biology · 2024Review
- Roles of circRNAs in regulating the tumor microenvironment.Medical oncology (Northwood, London, England) · 2023Review
- Targeting angiogenesis in oncology, ophthalmology and beyond.Nature reviews. Drug discovery · 2023Review
- Circ_0061140 Contributes to Ovarian Cancer Progression by Targeting miR-761/LETM1 Signaling.Biochemical genetics · 2023Article
- Tumour associated endothelial cells: origin, characteristics and role in metastasis and anti-angiogenic resistance.Frontiers in physiology · 2023Review
- [Exosomal miR-10b Promotes Invasion and Epithelial-mesenchymal Transformation of Lung Adenocarcinoma A549 Cells by Regulating Macrophage M2 Polarization].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Review
- Sphingosine 1-phosphate and its regulatory role in vascular endothelial cells.Histology and histopathology · 2022Review
- The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers.Cancer metastasis reviews · 2022Review
- Cancer Stem Cells and Their Vesicles, Together with Other Stem and Non-Stem Cells, Govern Critical Cancer Processes: Perspectives for Medical Development.International journal of molecular sciences · 2022Review
- The Long-Noncoding RNA TUG1 Regulates Oxygen-Induced Retinal Neovascularization in Mice via MiR-299.Investigative ophthalmology & visual science · 2022Article
- Mechanism underlying circRNA dysregulation in the TME of digestive system cancer.Frontiers in immunology · 2022Review
- A vasculogenic mimicry prognostic signature associated with immune signature in human gastric cancer.Frontiers in immunology · 2022Article
- Review
- Dual role of WNT5A in promoting endothelial differentiation of glioma stem cells and angiogenesis of glioma derived endothelial cells.Oncogene · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Anti-angiogenic therapies (AATs) have been widely used for cancer treatment. But the beneficial effects of AATs are short, because AAT-induced tumor revascularization facilitates the tumor relapse. In this mini-review, we described different forms of tumor neovascularization and revascularization including sprouting angiogenesis, vessel co-option, intussusceptive angiogenesis, and vasculogenic mimicry, all of which are closely mediated by vascular endothelial growth factor (VEGF), angiopoietins, matrix metalloproteinases, and exosomes. We also summarized the current findings for the resistance mechanisms of AATs including enhancement in pro-angiogenic cytokines, heterogeneity in tumor-associated endothelial cells (ECs), crosstalk between tumor cells and ECs, masking of extracellular vesicles, matrix stiffness and contributions from fibroblasts, macrophages and adipocytes in the tumor microenvironment. We highlighted the revascularization following AATs, particularly the role of exosome stimulating factors such as hypoxia and miRNA, and that of exosomal cargos such as cytokines, miRNAs, lncRNAs, and circRNAs from the tumor ECs in angiogenesis and revascularization. Finally, we proposed that renormalization of tumor ECs would be a more efficient cancer therapy than the current AATs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.